Skip to content
Biotechnology, Defence

Research to merge human brain cells with AI secures national defence funding

Monash University 2 mins read

Monash University-led research into growing human brain cells onto silicon chips, with new continual learning capabilities to transform machine learning, has been awarded almost $600,000 AUD in the prestigious National Intelligence and Security Discovery Research Grants Program.

The new research program, led by Associate Professor Adeel Razi, from the Turner Institute for Brain and Mental Health, in collaboration with Melbourne start-up Cortical Labs, involves growing around 800,000 brain cells living in a dish, which are then “taught” to perform goal-directed tasks. Last year the brain cells’ ability to perform a simple tennis-like computer game, Pong, received global attention for the team’s research.

According to Associate Professor Razi, the research program’s work using lab-grown brain cells embedded onto silicon chips, “merges the fields of artificial intelligence and synthetic biology to create programmable biological computing platforms,” he said. 

“This new technology capability in future may eventually surpass the performance of existing, purely silicon-based hardware.

"The outcomes of such research would have significant implications across multiple fields such as, but not limited to, planning, robotics, advanced automation, brain-machine interfaces, and drug discovery, giving Australia a significant strategic advantage."

The project garnered funding from the prestigious Australian grant body because the new generation of applications of machine learning, such as self-driving cars and trucks, autonomous drones, delivery robots, intelligent hand-held and wearable devices, “will require a new type of machine intelligence that is able to learn throughout its lifetime,” Associate Professor Razi said.  

This “continual lifelong learning” means machines can acquire new skills without compromising old ones, adapt to changes, and apply previously learned knowledge to new tasks—all while conserving limited resources such as computing power, memory and energy. Current AI cannot do this and suffers from “catastrophic forgetting”. 

In contrast, brains excel at continual lifelong learning. 

The project’s aim is to grow human brain cells in a laboratory dish, called the DishBrain system, to understand the various biological mechanisms that underlie lifelong continual learning.

“We will be using this grant to develop better AI machines that replicate the learning capacity of these biological neural networks. This will help us scale up the hardware and methods capacity to the point where they become a viable replacement for in silico computing,“  Associate Professor Razi said. 

For media enquiries please contact:

Monash University
Tania Ewing
E: [email protected] 
T: 0408 378 422

For more Monash media stories, visit our news and events site 

For general media enquiries please contact:
Monash Media
E: [email protected]
T: +61 (0) 3 9903 4840

 


Contact details:

Tania Ewing
0408 378 422
[email protected] 

More from this category

  • Biotechnology
  • 12/12/2025
  • 11:40
4DMedical Limited (ASX:4DX)

4DMedical secures $30.2 million with options underwrite

Highlights• $30.2 million in funding secured by entering into an underwriting agreement that ensures the exercise of all the 4DXO listed options• Additional funding results in a proforma cash balance as at 30 September 2025 of $63.7 million • 4DMedical is experiencing unprecedented interest in CT:VQ™, with multiple contract discussions underway, positioning CY26 as a transformational year Melbourne, Australia, 12 December 2025: 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”) today announces it has entered into an option underwriting agreement (Underwriting Agreement) with Bell Potter Securities Limited (Underwriter) to fully underwrite the exercise of the 4DXO listed options on issue,…

  • Biotechnology
  • 12/12/2025
  • 10:58
EBR Systems, Inc. (ASX:EBR)

First implant in the Totally Leadless CRT (TLC-AU) Study

Key Highlights • First patient enrolment and implant in the Totally Leadless CRT (TLC-AU) study by Dr Paul Gould from the Princess Alexandra Hospital, Brisbane • TLC-AU is a feasibility study into using the WiSE® System alongside a leadless pacemaker to achieve totally leadless CRT • The study represents a significant strategic milestone as EBR evaluates WiSE as a potential first-line therapy for treating newly diagnosed heart failure patients • TLC-AU could meaningfully expand EBR’s addressable market Sunnyvale, California; 12 December 2025: EBR Systems, Inc., developer of the world’s only wireless cardiac pacing device for heart failure, announces the first…

  • Biotechnology
  • 10/12/2025
  • 10:19
OncoSil Medical Limited (ASX:OSL)

First OncoSil treatment in United Kingdom

Sydney, Australia – 10 December 2025: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce the first commercial patient treatment in the UK using the OncoSil™ device. The successful treatment was performed on 9 December 2025 at Southampton General Hospital (University Hospital SouthamptonNHS Foundation Trust), a recognised centre of excellence in oncology. Following the hospital’s participation in the TRIPP-FFX clinical study, this significant milestone marks the transition from clinical trial involvement to the commencement of OncoSil’s commercial operations…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.